Enter multiple symbols separated by commas

Stocks Merck & Co Inc


  • LONDON— An experimental Ebola vaccine tested on thousands of people in Guinea seems to work and might help shut down the waning epidemic in West Africa, according to interim results from a study published Friday. There is currently no licensed treatment or vaccine for Ebola, which has so far killed more than 11,000 people in West Africa since the world's biggest...

  • Venezuela currency blues hit U.S. blue-chip companies Thursday, 30 Jul 2015 | 3:38 PM ET

    BOSTON, July 30- Venezuela's currency woes cut nearly $3 billion in profit at U.S. blue-chip companies during the second quarter and prompted Procter& Gamble Co to remove its operations in the South American country from its consolidated financial reports. More so-called deconsolidation moves and exits from Venezuela are likely to happen during the second...

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. Express Scripts, which administers drug benefits for employers and health plans and also runs large mail-order pharmacies, has been challenging...

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent new cholesterol drugs called PCSK9 inhibitors could "wreak financial havoc" among its clients. U.S. regulators on Friday approved the first of the new medicines, Praluent from Regeneron Pharmaceuticals Inc and Sanofi SA.

  • Harvoni and a second hepatitis C drug, Sovaldi, together posted sales about $500 million above expectations and HIV medicine sales were higher-than-expected across all products, noted Edward Jones analyst Ashtyn Evans. Gilead, based in Foster City, California, said Tuesday that its net income was $4.49 billion, or $2.92 per share. Revenue soared to $8.24...

  • Early movers: F, PFE, MRK, DD, WYN, DHI & more Tuesday, 28 Jul 2015 | 8:36 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Panda bear market

    U.S. stocks have some powerful negatives tugging at them, not the least of which are the Shanghai "panda bear" market and a global commodities rout.

  • Dissecting big pharma's numbers: Pro Tuesday, 28 Jul 2015 | 7:44 AM ET
    Dissecting big pharma's numbers: Pro

    Barbara Ryan, Clermont Partners, breaks down Pfizer and Merck's quarterly results and shares her outlook on the pharmaceutical sector.

  • Pfizer Inc. beat Wall Street's second-quarter expectations and raised its 2015 forecast, as soaring sales for a few key products helped inoculate the world's second-largest drugmaker against a $1 billion revenue hit from foreign exchange rates and its last wave of cheap generic competition hurting former big sellers. Pfizer's experimental drugs "could...

  • Merck& Co.' s second-quarter profit plunged by two-thirds, hammered by the sale of its consumer business, unfavorable currency exchange rates, lower sales of some key drugs and hefty one-time charges. The world's fifth-biggest drugmaker by revenue beat modest Wall Street expectations and raised its full-year profit forecast by a dime per share, but shares...

  • Minefield for market with Fed, earnings, commodities Monday, 27 Jul 2015 | 8:08 AM ET
    An oil trader works on the floor of the New York Mercantile Exchange.

    The Fed meets next week, but a commodities meltdown and earnings season are adding to concerns about global growth and may steal some of its thunder.

  • What to expect from Merck & Pfizer tomorrow Monday, 27 Jul 2015 | 6:52 AM ET
    What to expect from Merck & Pfizer tomorrow

    CNBC's Dominic Chu reports on Kensho studies, looking at Merck and Pfizer's stock performances around quarterly reports.

  • Allergan buys Naurex for $560M as deal talk swirls Sunday, 26 Jul 2015 | 11:20 AM ET
    A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan.

    Allergan is considering a breakup of the company into two businesses, a person familiar with the matter told Reuters on Friday.

  • TRENTON, N.J.— An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options— all much more effective but extremely costly— for patients with the liver-destroying virus. Daklinza, developed by New York- based Bristol-Myers Squibb Co., is the first drug approved to...

  • Buy the dip? Here's the bullish case now Friday, 24 Jul 2015 | 1:53 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Two Strategists favor U.S. stocks vs. global stocks

  • Health care takes earnings hot hand into week ahead Friday, 24 Jul 2015 | 10:23 AM ET
    Pfizer headquarters in New York.

    Health-care stocks are batting 12 for 12 in beating earnings estimates. Will the streak last?

  • Roche CEO warns on high pharma valuations Thursday, 23 Jul 2015 | 6:26 AM ET

    Valuation are "very high" in the pharmaceutical sector, Roche CEO Severin Schwan told CNBC on Thursday after the company posted a rise in sales.

  • July 20- Bristol-Myers Squibb Co said a late-stage trial of its drug, Opdivo, was stopped early after the immunotherapy was found to be effective in patients with the most common form of kidney cancer. The drug competes with Merck& Co's Keytruda. AstraZeneca Plc, Pfizer Inc and other drugmakers are also developing PD-1 inhibitors, or similar drugs known as PD-L1...

  • Cramer: Don't abandon finance & tech stocks, yet Thursday, 16 Jul 2015 | 6:12 PM ET
    Bank of America

    Jim Cramer says don't give up on the banks & tech stocks yet! Sometimes there is more than one way to skin a cat.

  • Stocks close up more than 1% amid Greece relief Monday, 13 Jul 2015 | 4:00 PM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks closed more than 1 percent higher, following gains overseas on news of a bailout agreement between Greece and its creditors.